QIAGEN Q2 Surge: Strong Earnings, Analyst Buy Ratings, Multi‑Omics Growth Boost
QIAGEN’s Q2 earnings surprise shows resilient margins and a booming multi‑omics pipeline, sparking analyst buy‑ratings and upward momentum for the diagnostics leader.
2 minutes to read








